reports
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present...
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the ...
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Eircom, Tele Columbus, Stada, Ahlstrom, AMS Osram, Aston Martin, Axactor, Constellium, Lowell, Vallourec, Versuni (formerly Philips Domestic Appliances), CEMEX, Engineering Group, Infopro Digital, Ineos, Motel One, Cerba, Polynt, Standard Profil, Air France-KLM, Crown Holdings, Recordati
VK VALLOUREC SA
CSTM CONSTELLIUM SE CLASS A
CCK CROWN HOLDINGS INC.
725180 STADA ARZNEIMITTEL AG
AF AIR FRANCE-KLM SA
TC1 TELE COLUMBUS AG
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
CEXA CEMEX SAB DE CV (ADR)
CERBA CERBA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS PLC
AXA AXACTOR SE
EIRCOM EIRCOM
Credit Agricole Nord de France - Avis de Mise a Disposition du Rapport...
Credit Agricole Nord de France - Avis de Mise a Disposition du Rapport Financier 2024 Lille, le 28 avril 2025 COMMUNIQUE AVIS DE MISE A DISPOSITION DU RAPPORT FINANCIER 2024 DU CREDIT AGRICOLE NORD DE FRANCE La Caisse régionale du Credit Agricole Nord de France annonce avoir mis à disposition du public et déposé auprès de l’Autorité des Marchés Financiers son rapport financier pour les comptes arrêtés au 31 décembre 2024. Le rapport peut être consulté sur le site de présentation du Crédit Agricole Nord de France à l’adresse , rubrique publications. Contact presse Crédit Agricole...
Vallourec Awarded a Major Contract by Kuwait Oil Company
Vallourec Awarded a Major Contract by Kuwait Oil Company Press release VALLOUREC AWARDED A MAJOR CONTRACT BY KUWAIT OIL COMPANY Meudon (France), April 28, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has secured a major contract to supply Oil Country Tubular Goods (OCTG) for the drilling operations of Kuwait Oil Company (KOC). This new contract represents over $130 million in potential revenue. This agreement includes the supply of carbon steel OCTG products with premium connections and proprietary steel grades, to be delivered in 2025 and 2026. Vallourec has ...
VALLOUREC SIGNE UN CONTRAT MAJEUR AVEC KUWAIT OIL COMPANY
VALLOUREC SIGNE UN CONTRAT MAJEUR AVEC KUWAIT OIL COMPANY Communiqué de presse VALLOUREC SIGNE UN CONTRAT MAJEUR AVEC KUWAIT OIL COMPANY Meudon (France), le 28 avril 2025 – Vallourec, un leader mondial des solutions tubulaires premium sans soudure, a remporté un contrat majeur pour la fourniture de tubes OCTG destinés aux opérations de forage de Kuwait Oil Company (KOC). Ce nouveau contrat représente un chiffre d’affaires potentiel de plus de 130 millions de dollars. Cet accord comprend la fourniture de tubes OCTG en acier carbone avec des connexions premium et des grades d’acier propri...
Credit Agricole Nord de France - Resultats Financiers au 31 Mars 2025
Credit Agricole Nord de France - Resultats Financiers au 31 Mars 2025 Lille, le 25 avril 2025 Résultats financiers au 31 Mars 2025 du Crédit Agricole Mutuel Nord de France Mars 2025 Mars 2024 Variation Activité : Encours de collecte globale 38 929 M€ 37 777 M€ 3,05% Encours de crédit* 28 728 M€ 28 703 M€ 0,09% Résultats sociaux* : Produit Net Bancaire 136,7 M€ 141,4 M€ -3,36% Résultat Brut d’Exploitation 32,5 M€ 42,9 M€ -24,15% Résultat Net 20,6 M€ 22,9 M€ -9,88% Résultats co...
Vallourec :
Vallourec : VALLOURECFrench limited liability company (société anonyme) with a Board of Directors with share capital of € 4,767,162.72 Registered office: 12, rue de la Verrerie – 92190 Meudon, FranceRegistered on the Nanterre Trade and Companies Register under n° 552 142 200 Meudon, April 24th, 2025 Monthly information relating to the total number of voting rightsand shares comprising the share capital Article L. 233-8-II of the French Code de commerce and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF) DateTotal numberof outstanding sharesTheoretic...
VALLOUREC :
VALLOUREC : VALLOURECSociété anonyme à Conseil d’Administrationau capital de 4 767 162,72 €Siège social : 12, rue de la Verrerie – 92190 Meudon552 142 200 RCS Nanterre Meudon, le 24 avril 2025, Information mensuelle relative au nombre total de droits de voteet d’actions composant le capital social Article L. 233-8-II du Code de commerce et article 223-16 du Règlement Général de l’Autorité des Marchés Financiers DateNombre totald'actions en circulationNombre totalde droits de vote théoriques (1)Nombre totalde droits de vote nets (2) 31 mars 2025238 139 535234 034 492234 034 49228 février ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREM...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial investigates the efficacy and safety of petrelintide in participants with overweight or obesity and type 2 diabetes. The ZUPREME-2 trial is designed to evaluate three doses of petrelintide up to 9 mg over 28 weeks of treatment. Co...
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to dri...
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to d...
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Tanvi Arora
Vallourec Wins a New Major Line Pipe Contract for Brazil's Buzios Offs...
Vallourec Wins a New Major Line Pipe Contract for Brazil's Buzios Offshore Field Press release VALLOUREC WINS A NEW MAJOR LINE PIPE CONTRACT FOR BRAZIL'S BUZIOS OFFSHORE FIELD Meudon (France), April 22, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces today that it has secured a major contract with Allseas to supply line pipes for Búzios 10 offshore project located at the Búzios field, operated by Petrobras. This contract represents nearly 18,000 tons of subsea seamless premium carbon steel line pipes, for the risers and flowlines. The contract includ...
VALLOUREC REMPORTE UN NOUVEAU CONTRAT MAJEUR DE PIPELINES POUR LE CHAM...
VALLOUREC REMPORTE UN NOUVEAU CONTRAT MAJEUR DE PIPELINES POUR LE CHAMP OFFSHORE DE BUZIOS AU BRÉSIL Communiqué de presse VALLOUREC REMPORTE UN NOUVEAU CONTRAT MAJEUR DE PIPELINES POUR LE CHAMP OFFSHORE DE BUZIOS AU BRÉSIL Meudon (France), le 22 avril 2025 – Vallourec, un leader mondial des solutions tubulaires premium sans soudure, annonce aujourd’hui la signature d’un contrat majeur avec Allseas pour la fourniture de pipelines dans le cadre du projet offshore Búzios 10, situé sur le champ de Búzios et opéré par Petrobras. Ce contrat représente près de 18 000 tonnes de solutions tubulair...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received inf...
Zealand Pharma launches long-term incentive programs for Zealand Pharm...
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025 Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incen...
Availability of information relating to the Combined (Ordinary and Ext...
Availability of information relating to the Combined (Ordinary and Extraordinary) Shareholders’ Meeting of 22 May 2025 Vallourec: Availability of information relating to the Combined (Ordinary and Extraordinary) Shareholders’ Meeting of 22 May 2025 Meudon (France), April 18, 2025 Vallourec's Ordinary and Extraordinary Shareholders' Meeting will be held on 22 May 2025 at 2:00 p.m. at Espace Verso, 52 rue de la Victoire 75009 Paris. The prior notice of meeting published in the Bulletin des Annonces Légales Obligatoires of April 7, 2025, the notice of meet...
Mise à disposition des informations relatives à l’Assemblée Générale M...
Mise à disposition des informations relatives à l’Assemblée Générale Mixte des actionnaires du 22 mai 2025 Vallourec : Mise à disposition des informations relatives à l’Assemblée Générale Mixte des actionnaires du 22 mai 2025 Meudon, France – le 18 avril 2025 L'Assemblée Générale Mixte des actionnaires de Vallourec se tiendra le 22 mai 2025 à 14 heures à l’Espace Verso, 52 rue de la Victoire, à Paris dans le 9ème arrondissement. L'avis de réunion publié au Bulletin des Annonces Légales Obligatoires le 7 avril 2025, la brochure de convocation de l'...
Vallourec Receives an Investment Grade Rating and Reports Positive Rat...
Vallourec Receives an Investment Grade Rating and Reports Positive Rating Actions by All Three Agencies VALLOUREC RECEIVES AN INVESTMENT GRADE RATINGAND REPORTS POSITIVE RATING ACTIONS BY ALL THREE AGENCIES Meudon (France), April 16, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces several positive developments in its credit outlook from S&P Global, Moody’s Ratings and Fitch Ratings. Specifically: Fitch Ratings upgraded Vallourec from BB+ to BBB-, an Investment Grade rating, with a stable outlook. This marks Vallourec’s first Investment Grade rating since...
VALLOUREC REÇOIT LA NOTATION « INVESTMENT GRADE » ET PUBLIE LES REVIS...
VALLOUREC REÇOIT LA NOTATION « INVESTMENT GRADE » ET PUBLIE LES REVISIONS A LA HAUSSE DES TROIS PRINCIPALES AGENCES DE NOTATION Communiqué de presse VALLOUREC REÇOIT LA NOTATION « INVESTMENT GRADE » ET PUBLIE LES REVISIONS A LA HAUSSE DES TROIS PRINCIPALES AGENCES DE NOTATION Meudon (France), le 16 avril 2025 – Vallourec, un leader mondial des solutions tubulaires premium sans soudure, annonce plusieurs révisions positives de ses perspectives de crédit de la part de S&P Global, Moody's Ratings et Fitch Ratings : Fitch Ratings a relevé la note de Vallourec de BB+ à BBB-, une note Investm...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.